Comparative study of safety and efficacy due to the dose change from 4 mg to 8 mg silodosin for benign prostatic hyperplasia with lower urinary tract symptoms.
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2014
At a glance
- Drugs Silodosin (Primary)
- Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
- Focus Pharmacodynamics; Therapeutic Use
- 04 Sep 2012 New trial record